Apogee Therapeutics, Inc. Investing Cash Flow
Apogee Therapeutics, Inc. (APGE) reported Investing Cash Flow of -$417.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Apogee Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$381.86M, a 588.78% decline year-over-year.
- Apogee Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$35.35M, a 372.29% decline year-over-year.
- Apogee Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$288.63M, a 722.48% decline year-over-year.
- Apogee Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $17.95M.
- Apogee Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$179.57M.
- Apogee Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$300.46M.
- Apogee Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$273.91M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$381.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$417.21M 10-Q · filed 2026-08-10 | -$705.84M derived: sum of 3 quarters · filed 2026-08-10 | -$687.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$35.35M 10-Q · filed 2026-05-11 | -$323.98M derived: sum of 2 quarters · filed 2026-05-11 | -$306.03M derived: sum of 3 quarters · filed 2026-05-11 | -$227.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$288.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$270.68M derived: sum of 2 quarters · filed 2026-03-02 | -$192.56M derived: sum of 3 quarters · filed 2026-08-10 | -$179.57M 10-K · filed 2026-03-02 |
| 2025-09-30 | $17.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $96.07M derived: sum of 2 quarters · filed 2026-08-10 | $109.05M 10-Q · filed 2025-11-10 | $155.42M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $78.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $91.11M 10-Q · filed 2026-08-10 | $137.47M derived: sum of 3 quarters · filed 2026-08-10 | -$8.90M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $12.98M 10-Q · filed 2026-05-11 | $59.35M derived: sum of 2 quarters · filed 2026-05-11 | -$87.03M derived: sum of 3 quarters · filed 2026-05-11 | -$235.74M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $46.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$100.01M derived: sum of 2 quarters · filed 2026-03-02 | -$248.72M derived: sum of 3 quarters · filed 2026-03-02 | -$300.46M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$146.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$295.09M derived: sum of 2 quarters · filed 2025-11-10 | -$346.83M 10-Q · filed 2025-11-10 | -$386.52M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$148.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$200.45M 10-Q · filed 2025-08-11 | -$240.14M derived: sum of 3 quarters · filed 2026-03-02 | |
| 2024-03-31 | -$51.74M 10-Q · filed 2025-05-12 | -$91.44M derived: sum of 2 quarters · filed 2026-03-02 | ||
| 2023-12-31 | -$39.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$273.91M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | -$234.22M 10-Q · filed 2024-11-12 |